Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

نتائج البحث

Display Settings
النتائج لكل صفحة: 10
Sort By: Relevance
Filter
  • 1-10 ل  77 نتائج ل ""Clinical Trials, Phase III as Topic""

فلترة النتائج

Subject : lung neoplasms
إعادة تعيين خيارات الفبترة
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Phase III, multicenter, randomized trial of 45 Gy versus 30 Gy thoracic radiation for extensive-stage small cell lung cancer (ES-SCLC): Study protocol.

  • Authors : Deng L; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.; Shayan G

Subjects: Small Cell Lung Carcinoma*/Small Cell Lung Carcinoma*/Small Cell Lung Carcinoma*/drug therapy ; Small Cell Lung Carcinoma*/Small Cell Lung Carcinoma*/Small Cell Lung Carcinoma*/radiotherapy ; Lung Neoplasms*/Lung Neoplasms*/Lung Neoplasms*/drug therapy

  • Source: Thoracic cancer [Thorac Cancer] 2024 Apr; Vol. 15 (11), pp. 938-943. Date of Electronic Publication: 2024 Mar 01.Publisher: Wiley Publishing Asia Pty Ltd Country of Publication: Singapore NLM ID: 101531441 Publication Model: Print-Electronic Cited Medium: Internet

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Phase II, double blind, placebo controlled, multi-site study to evaluate the safety, feasibility and desirability of conducting a phase III study of anamorelin for anorexia in people with small cell lung cancer: A study protocol (LUANA trial).

  • Authors : Sousa MS; Faculty of Health, Improving Palliative, Aged and Chronic Care through Clinical Research and Translation (IMPACCT), University of Technology Sydney, Ultimo, New South Wales, Australia.; School of Nursing and Midwifery, Western Sydney University, Penrith, New South Wales, Australia.

Subjects: Small Cell Lung Carcinoma*/Small Cell Lung Carcinoma*/Small Cell Lung Carcinoma*/complications ; Small Cell Lung Carcinoma*/Small Cell Lung Carcinoma*/Small Cell Lung Carcinoma*/drug therapy ; Lung Neoplasms*/Lung Neoplasms*/Lung Neoplasms*/complications

  • Source: PloS one [PLoS One] 2023 May 17; Vol. 18 (5), pp. e0285850. Date of Electronic Publication: 2023 May 17 (Print Publication: 2023).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Report

IMpower, CASPIAN, and more: exploring the optimal first-line immunotherapy for extensive-stage small cell lung cancer.

  • Authors : Huang C; Department of Respiratory and Critical Care Medicine II, The Affiliated Hospital of Southwest Medical University, 25 Taiping Street, Luzhou, 646000, Sichuan, China.; Division of Medical Oncology, Department of Internal Medicine, University of Kansas Cancer Center, University of Kansas Medical Center, 3005 Wahl Hall East, 3901 Rainbow Blvd, Kansas City, KS, 66160, USA.

Subjects: Clinical Trials, Phase III as Topic*/Clinical Trials, Phase III as Topic*/Clinical Trials, Phase III as Topic*/statistics & numerical data ; Immunotherapy*; Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*therapeutic use

  • Source: Journal of hematology & oncology [J Hematol Oncol] 2020 Jun 05; Vol. 13 (1), pp. 69. Date of Electronic Publication: 2020 Jun 05.Publisher: Biomed Central Country of Publication: England NLM ID: 101468937 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-8722

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings.

  • Authors : Hua T; Present Address: Department of Epidemiology and Health Statistics, School of Public Health, Southeast University, Nanjing, China.; Department of Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, China.

Subjects: Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/therapy ; Lung Neoplasms*/Lung Neoplasms*/Lung Neoplasms*/therapy; Biomarkers

  • Source: BMC cancer [BMC Cancer] 2022 Sep 29; Vol. 22 (1), pp. 1022. Date of Electronic Publication: 2022 Sep 29.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

[JCOG lung cancer surgery trial series: review and interpretation].

  • Authors : Li RZ; Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China.; Qiu B

Subjects: Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/surgery ; Lung Neoplasms*/Lung Neoplasms*/Lung Neoplasms*/surgery; Clinical Trials as Topic

  • Source: Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2022 Jul 23; Vol. 44 (7), pp. 703-711.Publisher: Chinese Medical Association Country of Publication: China NLM ID: 7910681 Publication Model: Print Cited Medium: Print ISSN: 0253-3766

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials.

  • Authors : Ma HC; Department of Oncology, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, 510120, China.; The Second Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou, 510120, China.

Subjects: Gene Rearrangement*; Anaplastic Lymphoma Kinase/Anaplastic Lymphoma Kinase/Anaplastic Lymphoma Kinase/*genetics ; Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*therapeutic use

  • Source: BMC cancer [BMC Cancer] 2021 Nov 26; Vol. 21 (1), pp. 1278. Date of Electronic Publication: 2021 Nov 26.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Determining the optimal PD-1/PD-L1 inhibitors for the first-line treatment of non-small-cell lung cancer with high-level PD-L1 expression in China.

  • Authors : Teng MM; Department of Pharmacy, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.; Chen SY

Subjects: B7-H1 Antigen/B7-H1 Antigen/B7-H1 Antigen/*analysis ; Carcinoma, Non-Small-Cell Lung/Carcinoma, Non-Small-Cell Lung/Carcinoma, Non-Small-Cell Lung/*drug therapy ; Immune Checkpoint Inhibitors/Immune Checkpoint Inhibitors/Immune Checkpoint Inhibitors/*therapeutic use

  • Source: Cancer medicine [Cancer Med] 2021 Sep; Vol. 10 (18), pp. 6344-6353. Date of Electronic Publication: 2021 Aug 12.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print-Electronic Cited Medium: Internet

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase III trial (STEREO-OS).

  • Authors : Thureau S; Radiation Oncology & Medical Physics Department, Henri-Becquerel Comprehensive Cancer Center, rue d'Amiens, F-76 000, Rouen, France. .; EA4108 QuantIf Litis, University of Rouen, 22 boulevard Gambetta, 76000, Rouen, France. .

Subjects: Bone Neoplasms/Bone Neoplasms/Bone Neoplasms/*surgery ; Breast Neoplasms/Breast Neoplasms/Breast Neoplasms/*surgery ; Carcinoma, Non-Small-Cell Lung/Carcinoma, Non-Small-Cell Lung/Carcinoma, Non-Small-Cell Lung/*surgery

  • Source: BMC cancer [BMC Cancer] 2021 Feb 04; Vol. 21 (1), pp. 117. Date of Electronic Publication: 2021 Feb 04.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Identification of Risk Factors and Likelihood of Benefit from Adjuvant Chemotherapy for Early Stage Lung Cancer Patients.

  • Authors : Moon H; Department of Mathematics and Statistics, California State University, Long Beach, CA, USA.; Chao T

Subjects: Adenocarcinoma of Lung/Adenocarcinoma of Lung/Adenocarcinoma of Lung/*drug therapy ; Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*administration & dosage ; Chemotherapy, Adjuvant/Chemotherapy, Adjuvant/Chemotherapy, Adjuvant/*statistics & numerical data

  • Source: Journal of biopharmaceutical statistics [J Biopharm Stat] 2020 May 03; Vol. 30 (3), pp. 430-444. Date of Electronic Publication: 2019 Oct 30.Publisher: Taylor & Francis Country of Publication: England NLM ID: 9200436 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Application of Machine Learning for Tumor Growth Inhibition - Overall Survival Modeling Platform.

  • Authors : Chan P; Clinical Pharmacology, Roche/Genentech, South San Francisco, California, USA.; Zhou X

Subjects: Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/drug therapy ; Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/mortality ; Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/pathology

  • Source: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2021 Jan; Vol. 10 (1), pp. 59-66. Date of Electronic Publication: 2020 Dec 13.Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
  • 1-10 ل  77 نتائج ل ""Clinical Trials, Phase III as Topic""